Transcript
Jim Cramer (0:00)
Meet Venu on the NYSE American Symbol Venu Disrupting a multi billion dollar live music industry, Venu owns and operates upscale music venues, outdoor amphitheaters with seven revenue sources $166 million in assets Luxury suite sales of $77 million in 2024 $200 million expected in 2025 56% year over year Growth venue on the NYSE American.
American Express Representative (0:29)
Venu when you're with AMEX Business Platinum, you have the card that works just as hard as you do. You give 150% to your business and so does your card. With 1.5 times Membership Rewards points on select purchases, you earn rewards that can take your business further. And with complimentary access to more than 1400 lounges globally, including the Centurion Lounge, you can stay up to speed no matter where your business takes you. That's the powerful backing of American Express terms and points Cap applied. Learn more@americanexpress.com AmExBusiness.
Jim Cramer (1:03)
My mission is simple, to make you money. I'm here to level the playing field for all investors. There's always a bull market somewhere and I promise to help you find it. Mad Money starts now. Hey, I'm Kramer. Welcome to Mad Money. Welcome to kramerica Friends. I'm just trying to make a little money. My job is not just to entertain, but to educate. So call me at 1-873-CBC-TOTCHEM Mitchell Kramer we had two sessions today. The first one was a great where Apple was soaring off its better than expected quarter and video stock was fighting its way higher and anything tech taken up with them. But then we had the second session dominated by anticipation of the White House slapping tariffs on Mexico, Canada, China. Sure enough, at 3:46pm we got 25% tariffs from Mexico and Canada, 10% tariffs from China. And the market which had been sagging, just slumped into the closing bell. Sell, sell, sell, sell. Yet that second session held sway with the Dow sinking 337 points as we losing.5%. Nasdaq declined point to 8%. Oh, and adding insult to injury, by the way, President Trump later came out and said he was, quote, not concerned about the market's reaction. I wish I had that luxury. We have a lot to cover. So let's go right to the game plan for next week. All right? The fireworks start on Monday. Well, of course we'll have to worry about the fallout, right of the tab, the tariffs. But Palantir's reporting after the close. Now Palantir is a really odd duck, so we're going to spend a second on it. Data driven consultant that helps everyone from packaged goods companies to the Pentagon to get more out of the resources. Right now they're focused on fixing the military procurement system. We give way too much business to a handful of defense contractors and it jacks up the price of all the hardware we we the taxpayers pay for. Now Palantir's voluble, volatile, unabashed CEO Alex Karp is a messianic figure to some in a Pied Piper. Others he caters to his retail investor base and the stocks a levitator. I call it Gamestop with the brain. I've been saying it's going to 100 ever since it was in the 50s. Now it's at 82 shows. No sign of letting up. Mark my words, $100 robust. Tuesday's jam packed. All right. Now we start the morning with PayPal and Spotify, both of which could have terrific numbers. PayPal is now being captained by Alex Kriss. I think he's returning the company to a solid growth mode. Now people used to be the king of digital mobile payments at one point. Then it fell in hard times as it frantically tried to play catch up to the buy now, pay later crowd. I believe Chris can restore the growth rate and the luster because PayPal serves as the digital wallet. That often is the first interaction that young people have with the payment system. Now Spotify is a classic beat race story that tends to blow away the estimates. I love these subscription businesses. You know that. Think Netflix, Amazon because of prime. And Spotify is always in the conversation. We also hear from two huge drug companies, Merck and Pfizer. Merck, despite some excellent acquisitions, is still about key, true to this revolutionary cancer treatment that just keeps working against so many different varieties of disease. I bet the numbers will be good, but there are other issues. I also want to get more of a readout on the drugs that Merck picked up in its recent wave of acquisitions. One for pulmonary arterial hypertension and a whole immunology franchise. Pfizer bought C gen, the old Seattle genetics at the end of 2023. We still haven't seen the breakout anti cancer drugs that would justify the deal's $43 billion price tag. Now maybe we'll hear something good this quarter. If so, the stock could soar. Very little downside at these low levels. The packaged food stocks have been dogs dogs ever since the GOP Dash 1 drugs burst on the scene, especially PepsiCo, one of my faves with its soft drink and snacks businesses. I think the new Weight loss drugs make it hard for the great this great company to play offense hasn't helped that the supermarket has become an inflation battleground. But PepsiCo yields 3.6%. You never know when you can catch a total rotation into this beaten down group. Then again, if you want yield this market, I'd much rather own Merck or Pfizer. After the close Alphabet reports and we want to find out if the search business is being cannibalized by its Gemini AI offering. I think YouTube is just on fire and that covers up any weakness. The new CFO and that Ashkenazi you might remember she was at Eli Lilly. She tells a terrific story. We'll be listening for anything about the growth of Google's cloud infrastructure business. If it is strong, the stock will fly. AMD has been quiet of late. I wonder if the chip maker has landed some big wins because in the wake of this deep seek affair which proved AI outfits can do more with less computing power, AMD's cheaper GPUs suddenly look a lot more attractive versus Nvidia's best of breed chips. All right, that's my thesis. Now let's see if it's true. Now we've been focused on a handful of great restaurant chains lately, especially the incredible rally in Brinker, which you know is Chili's. The premier growth stock in the group though has always been Chipotle. But somehow it's been lost in the shuffle here. Now maybe this is a chance to get back in before the next big move higher. Buying Chipotle and wages is generally the right call, like forever. Of course it has a new CEO, Scott Boatwright, but he's an old Chipotle hand. And the rest of the crew is intact, including friend of the show Jack Hartung, former cfo, now president and chief strategy officer. It might be time to start a position. Wednesday we get results from Walt Disney. Recent weather events could bring noise as hurricanes impacted Disney World last quarter. L A wildfires lucky impacted the outlook for Disneyland this quarter. But I think everything else is hitting on all cylinders including linear TV stocks put in put in its recent weakness behind it. This is historically cheaper which is why we've been telling members of the investing club to buy it. Novo Nordisk okay, now this is really interesting. See this is the drug company behind Ozempic. They report. Now maybe they can give us clarity about how well these drugs are doing because Eli Lilly has already announced soft fourth quarter sales but expects a very good 2025. We heard them when we were out in San Francisco I'd like to do the same thing. Novo Nordisk if you do get good news from Novo Norris, get this, you might want to buy some Eli Lilly before it reports on Thursday. At the close Wednesday we hear from Ford Motor. Ford's been a disappointment largely because of warranty costs, things that went wrong. But with long term interest rates high and likely going higher, their sales could be stalling. The stock's been awful so there's limited downside at these levels. I question the upside Thursday, more drugs. Yes, this is a tough drug week or aforementioned Eli Lilly reports while CEO David Ricks announced here on CNBC that 2025 will be a good year. We got to get some more details before we plow in. I remain steadfast. We have a big position for the trust. Next, another trust holding the Myers. They got a whole series of great drugs. But the one people are watching very closely is co benfi. That's the first two classes. Schizophrenia medications in 30 years. Far fewer side effects than the current standard of care. If they're really. You want to call that a standard of care, I bet CEO Chris Borner will give us some an early read of on prescriptions written this year. Now this could be a nice upside and I've got to tell you with that yield, it's one of my faves at the close Amazon portion. Although I predict terrific numbers, they might not be as terrific as they have to be to justify the stock's incredible recent run. We are for the Chapel Trust too. This is like our Chapel Trust week forever. It's a bonanza. But you may want to wait until after the quarter do any buying. That's not being. I'm not being negative. I'm just saying I don't want you after this big run to come in and then there'll be this give up because people are just taking profits. That's when you want to buy. Finally on Friday, we get the Labor Department's non farm payroll. Right now the Fed's concerned that the economy might be running too hot. If we get robust job growth with higher wages, then I doubt we'll see any rate hikes in the first half of the year. If you're rooting for a higher stock market, what do you really want to see? You want to so so employment report enough to keep rate cuts on the table, but not so much as to hurt corporations quarterly earnings. Bottom line, when you get a week that's packed with important earnings reports and the monthly employment report plus the tariff news, you're usually better off sitting on your hands because there's just too much data for any individual to process, even, even for an AI powered individual, by the way. Oh, let's just throw in this deep sea stuff which has made tech too maddening to buy or sell and too, let's say, boring. So if in doubt, do nothing. I want to go to my home state. I want to go to Sam in Pennsylvania. Sam.